Sugar chain added GLP-1 peptide
The present invention relates to an oligosaccharide chain added GLP-1 peptide that has higher stability in blood than that of GLP-1 and, preferably, exhibits higher activity of controlling blood-sugar levels than that of GLP-1. The present invention relates to an oligosaccharide chain added GLP-1 peptide having GLP-1 activity, wherein at least one amino acid is substituted with an oligosaccharide chain added amino acid, in: (a) GLP-1; (b) a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or (c) a GLP-1 analog.
1. An oligosaccharide chain added glucagon-like peptide-1 (GLP-1) peptide having GLP-1 activity, wherein one amino acid is substituted with an oligosaccharide chain added amino acid, wherein said oligosaccharide chain is not an O-linked oligosaccharide chain in GLP-1; wherein said oligosaccharide chain added GLP-1 peptide is:
(a) an oligosaccharide chain added GLP-1 peptide having one amino acid further added to the C terminal (position 37) of GLP-1, wherein said added amino acid is substituted with an oligosaccharide chain added amino acid;
(b) an oligosaccharide chain added GLP-1 peptide having one amino acid further added to the N terminal (position 7) of GLP-1, wherein said added amino acid is substituted with an oligosaccharide chain added amino acid; or
(c) an oligosaccharide chain added GLP-1 peptide wherein one or more amino acid site(s) selected from positions 18, 20, 22, 26, 30, 34 and 36 of GLP-1 is substituted with an oligosaccharide chain added amino acid; wherein: said oligosaccharide chain added amino acid is oligosaccharide chain added Asn; in said oligosaccharide chain added amino acid, the oligosaccharide chain is linked to the amino acid without a linker; said oligosaccharide chain consists of four or more sugars; and said oligosaccharide chain is selected from the group consisting of disialo, monosialo, asialo, diGlcNAc and dimannose oligosaccharide chains.
2. The oligosaccharide chain added GLP-1 peptide according to claim 1 , having at least one of the following properties:
higher stability in blood than that of GLP-1;
activity of controlling blood-sugar levels at least 10 times that of GLP-1 in OGTT (Oral Glucose Tolerance Test); and
DPP-IV resistance at least 30 times that of GLP-1.
3. A pharmaceutical composition comprising the oligosaccharide chain added GLP-1 peptide according to claim 1 for treating disease associated with GLP-1.
4. The pharmaceutical composition according to claim 3 , wherein said disease associated with GLP-1 is diabetes.
5. The pharmaceutical composition according to claim 4 wherein said oligosaccharide chain has at least 90% uniformity.
6. An oligosaccharide chain added glucagon-like peptide-1 (GLP-1) peptide having GLP-1 activity, wherein one amino acid is substituted with an oligosaccharide chain added amino acid, wherein said oligosaccharide chain added amino acid is oligosaccharide chain added Asn or oligosaccharide chain added Cys, wherein said oligosaccharide chain is not an O-linked oligosaccharide chain in GLP-1.
7. The oligosaccharide chain added GLP-1 peptide according to claim 6 , wherein in said oligosaccharide chain added amino acid, the oligosaccharide chain is linked to the amino acid without a linker.
8. The oligosaccharide chain added GLP-1 peptide according to claim 6 , wherein said oligosaccharide chain consists of four or more sugars.
9. The oligosaccharide chain added GLP-1 peptide according to claim 6 , wherein said oligosaccharide chain is selected from the group consisting of disialo, monosialo, asialo, diGlcNAc and dimannose oligosaccharide chains.
10. The oligosaccharide chain added GLP-1 peptide according to claim 6 , wherein said oligosaccharide chain is represented by the following formula:
wherein
R 1 and R 2 are the same or different and each represents
and
Ac represents an acetyl group.
11. The oligosaccharide chain added GLP-1 peptide according to claim 6 , having at least one of the following properties:
higher stability in blood than that of GLP-1;
activity of controlling blood-sugar levels at least 10 times that of GLP-1 in OGTT (Oral Glucose Tolerance Test); and
DPP-IV resistance at least 30 times that of GLP-1.
12. A pharmaceutical composition comprising the oligosaccharide chain added GLP-1 peptide according to claim 6 for treating disease associated with GLP-1.
13. The pharmaceutical composition according to claim 12 , wherein said disease associated with GLP-1 is diabetes.
14. The pharmaceutical composition according to claim 13 wherein said oligosaccharide chain has at least 90% uniformity.